Description
Triazavirin Pharmacodynamics
Active substance of TRIAZAVIRIN® is riamilovir, a synthetic analog of purine nucleoside bases (guanine) with expressed antiviral activity. It has a wide spectrum of antiviral activity against RNA-containing viruses.
The main mechanism of action of TRIAZAVIRIN® is inhibition of viral RNA synthesis and replication of genomic fragments.
Indications
As part of the complex therapy of influenza and other acute respiratory viral infections in adult patients.
Contraindications
– Hypersensitivity to the drug components;
– pregnancy;
– Breast-feeding period;
– Children under 18 years of age (efficacy and safety have not been determined);
– Renal/hepatic failure (efficacy and safety have not been determined).
Use in pregnancy and during breastfeeding
Because of lack of strictly controlled studies in humans, the drug is contraindicated for use during pregnancy (see section “Contraindications”).
Administration of the drug during breastfeeding has not been studied, therefore, if it is necessary to use the drug during lactation, breastfeeding should be stopped.
Dosage and administration regimen
- TRIAZAVIRIN® is taken orally with plenty of drinking water, independently of meals. The capsule should be swallowed whole; it is not recommended to chew or crush it.
- The drug should be started not later than the 2nd day from the beginning of the disease (manifestation of clinical symptoms of influenza and other acute respiratory viral infections).
- Recommended dosage:
- For influenza and other acute respiratory viral infections: 1 capsule (250 mg)
- 3 times a day for 5 consecutive days.
- Maximum single dose: 1 capsule (250 mg). Maximum daily dose: 3 capsules (750 mg).
- If within 5 days of treatment no improvement occurs or symptoms worsen, or new symptoms appear, consult a physician. Use the drug only according to the indications, the route of administration and the doses stated in the instructions.
